Joseph Moskowitz Sells Shares of Aflac Incorporated
Joseph Moskowitz sold 20,303 shares of Aflac on June 22, 2026.
Key Points
- Joseph Moskowitz sold 20,303 shares of Aflac Incorporated on June 22, 2026.
- Aflac trades at $117.58 with a market cap of $59.3 billion and a P/E ratio of 13.32.
- Analyst firms such as Piper Sandler and Morgan Stanley maintain varied ratings on Aflac.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Joseph Moskowitz sold 20,303 shares of Aflac Incorporated (NYSE: AFL). The transaction was not part of a planned trading program and did not specify a sale price or total value.
Insider Buying and Selling at Aflac Incorporated
Joseph Moskowitz was active in trading Aflac shares on June 22, 2026. Besides selling 20,303 shares, he also executed a purchase of the same amount at $44.59 per share. This activity was not pre-planned under Rule 10b5-1, indicating personal discretion in trading decisions.
Other Institutional Activity in Aflac Incorporated
Several institutional investors adjusted their positions in Aflac. Japan Post Holdings Co., Ltd. trimmed its stake by 325,500 shares, holding 51,974,500 shares valued at approximately $5.7 billion. BlackRock, Inc. also reduced its holdings by 572,535 shares, ending with 36,205,291 shares worth about $3.97 billion. On the other hand, Vanguard Capital Management LLC opened a new position with 30,254,403 shares, valued at $3.32 billion. Geode Capital Management, LLC increased its holdings by 248,274 shares, now holding 10,717,264 shares valued at $1.17 billion.
Aflac Incorporated Stock Up 2.9%
Shares of Aflac traded near $117.58 on Wednesday. The company has a market cap of $59.3 billion, a P/E ratio of 13.32, and a forward P/E of 15.33. Its beta is 0.61, reflecting lower volatility compared to the market. The stock's 52-week range is $96.95 to $119.81, with a 50-day moving average of $115.10 and a 200-day moving average of $111.45. Aflac's financial health is supported by a current ratio of 0.935 and a debt-to-equity ratio of 48.28.
$AFL stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Aflac reported revenue of $18.11 billion, with a revenue growth of 27.9%. The company achieved a net margin of 25.6% and a return on equity of 16.5%. Its earnings per share stood at $8.75. The next earnings release is scheduled for August 6, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS missed estimates by 4.4%. Revenue beat estimates by 1.1%.
-
Profit surprise
Operating income beat by 13 percent.
-
Pre-earnings setup
Bar was low, analysts cautious going in.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Gross margin up 43.4 points. Operating margin up 24.2 points.
Earnings Call Summary
Aflac Japan delivered strong sales growth of 25.5 percent in the quarter, driven by new medical and cancer insurance products, though underlying earned premiums still declined 1.3 percent due to lapses of paid-up policies. In the United States, net earned premiums grew 3.5 percent with solid persistency of 79.3 percent. Management noted that Japan would need about 80 billion yen in annual sales to reach flat earned premium growth, versus 74 billion achieved in 2025.
Guidance Aflac expects Japan benefit ratio between 60 percent and 63 percent for the full year, roughly in line with first quarter results. For the United States, they forecast a benefit ratio of 42 percent to 52 percent. The company plans to continue share buybacks and dividend increases, returning $1.3 billion to shareholders in the first quarter alone.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Dividend
Aflac pays an annual dividend rate of $2.44, yielding 2.11%. The dividend payout ratio is 26.9%, indicating a sustainable distribution policy.
Analysts Set New Price Targets
Analyst firms have maintained their ratings on Aflac. On May 26, 2026, Piper Sandler maintained a 'buy' rating with a price target of $130. Morgan Stanley reiterated its 'hold' rating with a target of $125 on May 21, 2026. The consensus recommendation is to hold, with an average target price of $112.43 based on 14 analyst opinions.
About Aflac Incorporated
Aflac Incorporated provides supplemental health and life insurance products through its subsidiaries. Operating in the United States and Japan, Aflac offers various insurance products, including cancer, medical, and life insurance. Headquartered in Columbus, Georgia, and led by CEO Daniel Amos, Aflac employs approximately 12,716 people.
Bottom Line
Joseph Moskowitz's recent sale of Aflac shares adds to the complex picture of insider activity, which investors often watch closely. Aflac continues to show strong financial health with robust earnings and a stable dividend. Analysts maintain a range of ratings, reflecting mixed sentiment about the company's future performance.
Get Aflac Incorporated alerts
New 13F filings, insider trades, and analyst moves on $AFL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.